XML 63 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Additional Information (Detail)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
USD ($)
Segment
vial
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]        
Number of operating segment | Segment   1    
Cash, cash equivalents and marketable securities   $ 191,900,000    
Impairment of Intangible assets   0    
Impairments of tangible assets   0 $ 0 $ 0
Goodwill impairments   $ 0 $ 0 $ 0
Federal corporate income tax rate   35.00%    
New Corporate Tax Rate        
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]        
Federal corporate income tax rate 21.00%      
HEPLISAV-B™        
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]        
Number of vials | vial   250,000    
Expected minimum selling period   9 months    
United States        
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]        
Percentage of revenue earned   90.00% 92.00% 85.00%
Percentage of long lived assets   15.00% 17.00%  
Maximum        
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]        
Cash equivalents original maturity period   3 months    
Dynavax GmbH        
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]        
Currency translation adjustments   $ 2,800,000 $ (700,000) $ (1,300,000)
Currency transaction (loss) gain   $ (600,000) $ 200,000 $ 100,000